Global Prothrombin Complex Concentrate Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Prothrombin Complex Concentrate Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Market Overview:

The latest research study on the global Prothrombin Complex Concentrate market finds that the global Prothrombin Complex Concentrate market reached a value of USD 784.24 million in 2022. It’s expected that the market will achieve USD 1048.45 million by 2028, exhibiting a CAGR of 4.96% during the forecast period.

Opportunities

Clinical studies have demonstrated that fresh frozen plasma requires longer infusion times than prothrombin complex concentrate (PCC). In addition to infusion time, prothrombin complex concentrate has other advantages over FFP. Some of the remarkable properties that have led to the increasing adoption of prothrombin complex concentrates are their ability to undergo remodeling in a short period of time. In addition to the above factors, the better safety of prothrombin complex concentrate affects the user's preference for fresh frozen plasma.
Since its FDA approval, Kcentra has been adopted by many healthcare professionals worldwide. Kcentra has proved effective in restoring blood clotting because it contains certain factors that help replenish various clotting factors. Kcentra plays an important role in the treatment of patients treated with warfarin. Warfarin can cause severe and acute blood loss and minimize such loss and recovery factors, and Kcentra has been shown to be beneficial. Therefore, the use of PCC in warfarininduced bleeding has led to an increase in the adoption rate, which in turn has driven the development of the global market.
The latest update on the licensing policy for prothrombin complex concentrate bodes well for development. Globally, there has been a relaxation in the use of PCC in the treatment of hemorrhagic disorders. This has encouraged research analysts and others involved to conduct more clinical trials and to present newer usage concepts to regulators. In addition, increased government funding to promote the use of PCC in surgical procedures is driving the global market. The effective clinical efficiency of PCC has encouraged governments around the world to promote the use of PCC to treat unnecessary bleeding during surgery.

Region Overview:

North America had the highest growth rate of all regions.

Company Overview:

CSL Behring is one of the major players operating in the Prothrombin Complex Concentrate market, holding a share of 40.51% in 2020.

Grifols said on March 8, 2019 that it will acquire a 26.2 percent stake in Shanghai raz for $1.9 billion as part of its strategic alliance to produce, market and develop plasma derivatives and blood transfusion diagnostic solutions in the Chinese market. After the deal closes, Grifols will become the second-largest shareholder in raz, behind Creat Group Corporation, which owns 26.7 per cent of the company. The remaining capital will be distributed among institutional investors and minority shareholders.

CSL limited (ASX: CSL; USOTC: CSLLY) announced today that it has completed the completion of its joint venture with renfu pharmaceutical group co., ltd. and acquired a majority stake in Wuhan Zhong yuan ruide biological products co., LTD., a blood products manufacturer. Through this new partnership with renfu, gertbeilin hopes to leverage its global expertise to help rare and critically ill patients in China.

Segmentation Overview:

Among different product types, 4 Factor Prothrombin Complex Concentrate segment is anticipated to contribute the largest market share in 2028.

Application Overview:

By application, the Hospitals segment occupied the biggest share from 2018 to 2022.

Key Companies in the global Prothrombin Complex Concentrate market covered in Chapter 3:

Kedrion S.p.A
Grifols
Octapharma AG
CSL Behring
Hualan Bio
China Biologic Products Holdings Inc.

In Chapter 4 and Chapter 14.2, on the basis of types, the Prothrombin Complex Concentrate market from 2018 to 2029 is primarily split into:

3 Factor Prothrombin Complex Concentrate
4 Factor Prothrombin Complex Concentrate

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Prothrombin Complex Concentrate market from 2018 to 2029 covers:

Hospitals
Clinics
Ambulatory Surgical Centers

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)